5 years ago

Ori Biotech Secures $30 Million in Series A to Advance Cell and Gene Therapy Manufacturing

  • Ori Biotech, a cell and gene therapy (CGT) manufacturing company based in London, UK and New Jersey, US, has raised $30 million in Series A funding

  • The round was led by Northpond Ventures, with participation from Octopus Ventures, Amadeus Capital Partners, Delin Ventures, and Kindred Capital

  • Ori plans to use the funds to bring its manufacturing platform to market

  • The Ori platform offers scalable solutions for CGT developers, providing flexibility to meet their clinical and commercial manufacturing needs.

      • ProblemHealthcare

      "Cell and gene therapy developers struggle with scaling their manufacturing processes to meet clinical and commercial needs."

      Solution

      "Ori Biotech has developed a flexible manufacturing platform that automates and standardizes the manufacturing process, enabling developers to scale up their products from pre-clinical development to commercial-scale production."

      Covered on